1832 Asset Management L.P. Has $20.63 Million Position in Pfizer Inc. $PFE

Key Points

• 1832 Asset Management L.P. significantly reduced its stake in Pfizer Inc. by 92.4%, selling 9,955,299 shares and holding only 814,281 shares, valued at $20.6 million after the sale.
• Pfizer reported a quarterly revenue of $14.65 billion, exceeding estimates, with earnings per share of $0.78, up from $0.60 the previous year.
• The company announced a quarterly dividend of $0.43 per share, representing a 6.7% yield, payable on September 2nd to stockholders on record as of July 25th.

1832 Asset Management L.P. cut its position in Pfizer Inc. (NYSE:PFE - Free Report) by 92.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 814,281 shares of the biopharmaceutical company's stock after selling 9,955,299 shares during the period. 1832 Asset Management L.P.'s holdings in Pfizer were worth $20,634,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Clarity Asset Management Inc. acquired a new stake in Pfizer in the fourth quarter worth $27,000. Gould Capital LLC raised its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the first quarter worth $27,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter worth $28,000. Finally, North Capital Inc. acquired a new stake in shares of Pfizer during the first quarter worth $28,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 2.8%

PFE traded down $0.73 during trading on Monday, reaching $25.15. 32,304,503 shares of the company's stock were exchanged, compared to its average volume of 44,473,524. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $142.99 billion, a PE ratio of 13.38, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The firm has a fifty day moving average price of $24.72 and a two-hundred day moving average price of $24.39.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Bank of America raised their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Berenberg Bank decreased their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Finally, UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.